Hs016, a proposed adalimumab biosimilar, showed equivalent pharmacokinetics and similar safety, immunogenicity and tolerability to china-licensed adalimumab in healthy male subjects, according to a 2.3-months phase i study

Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2019
This article has no abstract
Epistemonikos ID: 2cfc158199db938c6946286897eeda5584aaf171
First added on: Feb 11, 2025